CG Oncology CEO Arthur Kuan leads the applause as the company rings the Nasdaq opening bell on Jan. 25, 2024 (Kyle LaHucik for Endpoints News)

Is CG On­col­o­gy’s IPO a bench­mark for a bet­ter year in pub­lic of­fer­ings? 

NEW YORK — CG On­col­o­gy rang the Nas­daq open­ing bell on Thurs­day morn­ing, mark­ing a rare sight for biotechs over the past two years as the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.